BIOMAT Database Logo BIOMAT Database Logo

High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. 2013

E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
Haematoncology Division, European Institute of Oncology, Milan, Italy. emilia.cocorocchio@ieo.it

High-dose chemotherapy (HDCT) has a consolidated role in the treatment of patients with refractory or relapsed Hodgkin lymphoma (HL). We report clinical results of 97 HL patients who underwent HDCT for refractory (62 patients) or relapsed (35 patients) diseases in Istituto Europeo di Oncologia, from 1995 to 2009. Treatment included high-dose carmustine, etoposide, cytarabine and melphalan in 84 patients and high-dose idarubicin and melphalan in 13 patients with subsequent peripheral hemopoietic stem cells transplant. Outcomes were evaluated in terms of progression-free survival (PFS) and overall survival (OS). In order to identify prognostic factors for outcome, a multivariate analysis for age, sex, disease status (refractory/relapsed), disease stage, B symptoms, presence of extranodal involvement, bulky disease, elevated lactate dehydrogenase, number of previous chemotherapy lines, remission status before transplant, 18F-fluoro-deoxy-d-glucose positron emission tomography ((18) FDG-PET) status before and after transplant was done. A clinical response was achieved in 91% of patients, with complete remissions in 76/97 patients. With a median follow-up of 45 months (range 1-164 months), 5-year PFS and OS were 64% and 71%, respectively. Remission status after induction therapy, 18F-fluoro-deoxy-d-glucose positron emission tomography status before and after transplant were the most important prognostic factors for PFS and OS in univariate or multivariate analyses. HDCT is able to induce a high remission rate and a prolonged PFS in more than 50% of the patients with refractory and relapsed HL.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma.
February 2013, International journal of hematology,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.
September 2007, Leukemia & lymphoma,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients.
December 2013, Immunotherapy,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
June 2013, The Cochrane database of systematic reviews,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
January 2016, Annals of hematology,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
January 2016, British journal of haematology,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.
March 2021, Journal of clinical and experimental hematopathology : JCEH,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
September 2016, Cancer investigation,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
Pembrolizumab for relapsed or refractory Hodgkin lymphoma.
June 2021, The Lancet. Oncology,
E Cocorocchio, and F Peccatori, and A Vanazzi, and G Piperno, and L Calabrese, and E Botteri, and L Travaini, and L Preda, and G Martinelli
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.
February 2010, British journal of haematology,
Copied contents to your clipboard!